Delivery Order 36F79720D0099-36C25220F0443
Award Date 9/9/20
Potential Completion Date 10/10/20
Potential Value $10K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a delivery order valued at $10,102.19 to Otsuka America Pharmaceutical Inc. on April 15, 2020, for the supply of Tolvaptan, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. This firm fixed-price delivery order, with performance in Pittsburgh, Pennsylvania, does not utilize a set-aside designation and is issued under the Pharmaceuticals and Drugs...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a $10,102.19 firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan on July 9, 2020, with a completion date of July 31, 2020. The delivery order was issued under the company's existing Blanket Purchase Agreement on the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Tolvaptan, marketed as Jynarque, is a specialized pharmaceutical used to treat autosomal dominant...
- On August 3, 2020, the Department of Veterans Affairs, through Veterans Integrated Service Network 12, awarded a delivery order to Otsuka America Pharmaceutical Inc. for the supply of Tolvaptan with a ceiling value of $10,102.19. This firm-fixed price delivery order, with an ultimate completion date of August 10, 2020, was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize a set-aside designation. The place of performance is Pittsburgh,...
- On May 7, 2020, the Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a $10,102.19 firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan. This contract represents a delivery order issued under the company's larger Blanket Purchase Agreement valued at $83.3 million for Jynarque (tolvaptan), awarded by the VA's National Acquisition Center under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Tolvaptan is a specialized...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a $10,102.19 delivery order to Otsuka America Pharmaceutical Inc. on June 8, 2020, for Tolvaptan, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. This firm-fixed-price delivery order, which was completed by June 30, 2020, was issued without any set-aside designation and is to be performed in Pittsburgh, Pennsylvania. The contract was executed under...
- The Department of Veterans Affairs, Veterans Integrated Service Network 9, awarded a delivery order to Otsuka America Pharmaceutical Inc. on August 18, 2020, for specialty medication tolvaptan in dose-pack formulations (15mg and 45mg). The contract, valued at approximately $20,000, was executed as a firm fixed-price delivery order with no set-aside designation and a performance location in Potomac, Maryland. Tolvaptan, marketed under the brand name Jynarque, is utilized in the VA healthcare...
- On October 1, 2021, the Department of Veterans Affairs, Veterans Integrated Service Network 22, awarded a delivery order valued at $146,493.98 to Otsuka America Pharmaceutical Inc. for the supply of Tolvaptan (brand name Jynarque), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. This firm fixed-price delivery order, with an ultimate completion date of July 7, 2023, was issued without a set-aside designation and...
- The Department of Veterans Affairs, Veterans Integrated Service Network 21, awarded a delivery order valued at $12,580.72 to Otsuka America Pharmaceutical Inc. for the supply of Tolvaptan on February 15, 2024, with an ultimate completion date of May 14, 2024. This firm fixed-price delivery order does not utilize a set-aside designation and is being performed in Potomac, Maryland. The award falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents a task order...
- On September 11, 2020, the Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 9, awarded a firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for tolvaptan hormone drug emergency supply. The contract ceiling value is $10,034.63 and is scheduled for completion by September 18, 2020. Tolvaptan, marketed as Jynarque, is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. This delivery order...
- On June 5, 2020, the Department of Veterans Affairs, specifically Veterans Integrated Service Network 6 (VISN 6), awarded a $10,034.63 delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract was awarded on a firm-fixed price basis without set-aside designation and was delivered to a location in Potomac, Maryland, with an ultimate completion date...